Medically Reviewed and Compiled by Dr. Adam N. Khan, MD.
What Is Metastatic Prostate Cancer?
Metastatic prostate cancer is prostate cancer that has spread beyond the prostate gland to other parts of the body. It most often spreads to:
- Bones
- Lymph nodes
- Liver
- Lungs
When prostate cancer spreads, doctors call it Stage IV or advance
Medically Reviewed and Compiled by Dr. Adam N. Khan, MD.
What Is Metastatic Prostate Cancer?
Metastatic prostate cancer is prostate cancer that has spread beyond the prostate gland to other parts of the body. It most often spreads to:
- Bones
- Lymph nodes
- Liver
- Lungs
When prostate cancer spreads, doctors call it Stage IV or advanced prostate cancer.
According to the American Cancer Society, prostate cancer is one of the most common cancers in men in the United States. Many cases are found early. However, some cases spread before or after treatment.
Metastatic prostate cancer treatment focuses on:
- Slowing cancer growth
- Reducing symptoms
- Improving quality of life
- Extending survival
Treatment depends on where the cancer has spread, prior treatments, and overall health.
How Doctors Diagnose Metastatic Disease
Doctors use several tests to confirm spread:
Blood Tests
- PSA (Prostate-Specific Antigen) levels
- High PSA may suggest progression
Imaging Tests
- Bone scan
- CT scan
- MRI
- PSMA PET scan
The National Cancer Institute states that imaging helps determine how far the cancer has spread and guides treatment planning.
Main Goals of Metastatic Prostate Cancer Treatment
Metastatic prostate cancer is usually not curable. Treatment is long-term and focused on control.
Goals include:
- Lowering testosterone levels
- Shrinking tumors
- Relieving bone pain
- Preventing fractures
- Extending survival
The National Comprehensive Cancer Network (NCCN) provides clinical guidelines that shape most treatment decisions in the U.S.
Hormone Therapy (Androgen Deprivation Therapy)
Why Hormone Therapy Works
Prostate cancer cells depend on male hormones called androgens, mainly testosterone. Lowering testosterone slows cancer growth.
This treatment is called:
- Androgen Deprivation Therapy (ADT)
According to the American Society of Clinical Oncology (ASCO), ADT is the backbone of metastatic prostate cancer treatment.
Types of Hormone Therapy
LHRH Agonists and Antagonists
These drugs stop the testicles from making testosterone.
Examples include:
- Leuprolide
- Goserelin
- Degarelix
These medications are given as injections.
Anti-Androgen Pills
These block testosterone from attaching to cancer cells.
Common drugs:
- Enzalutamide
- Apalutamide
- Darolutamide
These are often combined with ADT for better results.
The New England Journal of Medicine has published large trials showing improved survival when combining ADT with newer anti-androgen medications.
Side Effects of Hormone Therapy
- Hot flashes
- Fatigue
- Weight gain
- Bone thinning
- Loss of muscle
- Mood changes
Doctors monitor bone health and may prescribe calcium, vitamin D, or bone-strengthening drugs.
Chemotherapy
When Chemotherapy Is Used
Chemotherapy is often used when:
- Cancer spreads widely
- Hormone therapy stops working
- Symptoms worsen
The most common drug is docetaxel.
Research published in the New England Journal of Medicine shows that adding docetaxel early to hormone therapy improves survival in certain patients.
Common Side Effects
- Hair loss
- Nausea
- Low blood counts
- Infection risk
- Fatigue
Doctors monitor blood levels carefully during treatment.
Targeted Therapy
Targeted therapy attacks specific cancer cell changes.
PARP Inhibitors
These drugs work for men with specific gene mutations such as BRCA1 or BRCA2.
Examples:
- Olaparib
- Rucaparib
The National Cancer Institute confirms that genetic testing helps identify patients who benefit from these drugs.
PSMA-Targeted Radioligand Therapy
This newer therapy attaches radiation to a molecule that targets prostate cancer cells.
Example:
- Lutetium-177–PSMA
Clinical studies reported in peer-reviewed journals show benefit in advanced cases after other treatments fail.
Immunotherapy
Immunotherapy helps the immune system attack cancer.
Sipuleucel-T
This is a personalized vaccine therapy. It is used in select patients with minimal symptoms.
According to the U.S. Food and Drug Administration (FDA), sipuleucel-T improves survival in some men with metastatic disease.
Radiation Therapy
Radiation may be used to:
- Relieve bone pain
- Prevent fractures
- Control specific tumor areas
External beam radiation is common.
The American Society for Radiation Oncology (ASTRO) supports radiation for symptom control in metastatic bone disease.
Bone-Strengthening Treatments
Since metastatic prostate cancer often spreads to bone, doctors use:
- Zoledronic acid
- Denosumab
These drugs reduce fractures and bone complications.
The National Comprehensive Cancer Network (NCCN) recommends bone-protective agents in men with bone metastases.
Managing Treatment Resistance
Over time, many patients develop:
- Castration-Resistant Prostate Cancer (CRPC)
This means cancer grows even when testosterone is very low.
Treatment options at this stage include:
- Second-line hormone therapy
- Chemotherapy
- Targeted therapy
- Clinical trials
The American Cancer Society explains that treatment sequencing is critical for better outcomes.
Unique Clinical Takeaways
1. Genetic Testing Should Be Standard, Not Optional
Many patients do not realize that inherited gene mutations affect treatment.
Men with:
- BRCA1
- BRCA2
- ATM mutations
May qualify for targeted therapy.
The National Cancer Institute recommends both tumor and germline genetic testing in metastatic prostate cancer.
Actionable Insight:
Patients should request genetic testing early, even if no strong family history exists.
2. Bone Health Is a Central Survival Issue
Bone metastases are not just painful. They increase:
- Fracture risk
- Spinal cord compression
- Hospitalizations
According to NCCN guidelines, bone-protective therapy should begin when bone metastases are diagnosed.
Actionable Insight:
Ask about bone density scans and start prevention early, not after fractures occur.
3. Early Combination Therapy Improves Outcomes
Older treatment models started with hormone therapy alone.
Large randomized trials published in the New England Journal of Medicine show that combining:
- ADT + chemotherapy
OR - ADT + novel hormone agents
Improves survival compared to ADT alone.
Actionable Insight:
Patients should discuss upfront combination therapy rather than delayed treatment escalation.
4. Symptom Burden Guides Treatment Choice
Patients with:
- High pain
- Extensive bone spread
- Rapid PSA rise
Often benefit from aggressive early treatment.
Those with low-volume disease may qualify for different strategies.
The American Society of Clinical Oncology (ASCO) emphasizes tailoring therapy based on disease burden.
Actionable Insight:
Accurate staging and symptom reporting influence survival outcomes.
Clinical Trials
Clinical trials test new therapies.
Patients may gain access to:
- Experimental drugs
- Combination therapies
- Novel immunotherapies
The National Cancer Institute maintains a clinical trial registry for advanced prostate cancer.
Survival Rates and Outlook
Survival varies widely.
Factors include:
- Extent of spread
- Response to treatment
- Overall health
- Genetic mutations
The American Cancer Society reports that the 5-year relative survival rate for distant metastatic prostate cancer is lower than localized disease, but new treatments continue to improve outcomes.
Living With Metastatic Prostate Cancer
Treatment is ongoing.
Patients often need:
- Long-term follow-up
- PSA monitoring
- Imaging scans
- Bone health evaluation
- Emotional support
Multidisciplinary care improves outcomes. This includes:
- Medical oncologists
- Urologists
- Radiation oncologists
- Palliative care specialists
The National Comprehensive Cancer Network supports team-based care for advanced cancers.
References and Citations
- American Cancer Society – Prostate Cancer Facts and Treatment Guidelines (internal reference)
- National Cancer Institute – Metastatic Prostate Cancer Treatment Overview (internal reference)
- National Comprehensive Cancer Network (NCCN) – Clinical Practice Guidelines in Oncology: Prostate Cancer (internal reference)
- American Society of Clinical Oncology (ASCO) – Advanced Prostate Cancer Management Guidelines (internal reference)
- New England Journal of Medicine – Randomized Trials on ADT plus Docetaxel and Novel Hormonal Agents (internal reference)
- U.S. Food and Drug Administration – Approval Summary for Sipuleucel-T (internal reference)
- American Society for Radiation Oncology (ASTRO) – Radiation for Bone Metastases Guidelines (internal reference)
Medical Disclaimer
This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider regarding medical conditions or treatment decisions